Huakang Biomedical Holdings Company Limited (8622) Stock Statistics & Valuation Metrics

Huakang Biomedical Holdings Company Limited has a market cap or net worth of HK$177.67M. The enterprise value is HK$37.48M.

Huakang Biomedical Holdings Company Limited has 500,472,000 shares outstanding. The number of shares has decreased by -2.65% in one year.

Huakang Biomedical Holdings Company Limited’s return on equity (ROE) is -0.11 and return on invested capital (ROIC) is -11.54%.

The current PE Ratio of Huakang Biomedical Holdings Company Limited is -6.97. Huakang Biomedical Holdings Company Limited’s PEG ratio is -0.08.

In the last 12 months, Huakang Biomedical Holdings Company Limited had revenue of 24.63M and earned -5.78M in profits. Earnings per share was -0.01.

In the last 12 months, operating cash flow was -2.82M and capital expenditures 0.00, giving a free cash flow of -2.82M billion.

Huakang Biomedical Holdings Company Limited pays an annual dividend of ―, resulting in a dividend yield of ―

Huakang Biomedical Holdings Company Limited upcoming earnings date is May 13, 2025, TBA Not Confirmed.

Huakang Biomedical Holdings Company Limited as a current ratio of 4.08, with Debt / Equity ratio of 8.18%

In the past 12 months, Huakang Biomedical Holdings Company Limited has paid 0.00 in taxes.

Huakang Biomedical Holdings Company Limited EV to EBITDA ratio is -4.91, with an EV/FCF ratio of -8.08.

Huakang Biomedical Holdings Company Limited has HK$36.66M in cash and marketable securities with ¥0.00 in debt, giving a net cash position of -HK$32.03M billion.

Gross margin is 65.94%, with operating margin of -26.32%, and net profit margin of -23.48%.

The average price target for Huakang Biomedical Holdings Company Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―